Skip to main content

Table 2 Baseline, final, and change values for the included studies

From: Effect of metformin on left ventricular mass and functional parameters in non-diabetic patients: a meta-analysis of randomized clinical trials

Author LVMI (g/m2) LVEF (%) NT-ProBNP E/e′ ratio
E C E C E C E C
Ali [32] B: 89 (75, 105) B: 85 (73, 101) B: 52 (45, 59) B: 52 (46, 57) B: 79.5 (42, 179) B: 68 (37, 177) B;7.8 (6.7, 9.6) B:7.1 (5.9, 9.7)
F4: 88.4 (75.7, 100.9) F4: 85.7 (73.6, 97.0) F4: 55 (48, 60) F4: 58 (53, 63) F4:7.6 (6.4, 9) F4:7.5 (6.2, 8.7)
4: − 2.7 (− 16.0, 6.9) 4: 0.6 (− 13.5, 9.1) 4: 3.2 (− 2.9, 7.6) 4: 3.7 (0.3, 10.6) 4: − 0.1 (− 1.3, 1.0) 4:0.2 (− 1.3, 1.9)
Gupta [33]    B: 46.0 (36.0–56.0) B: 43.0 (33.0–50.0) B: 996 (333–1798) B: 903 (464–1378)   
F12: 51.0 (42.0–61.0) F12: 45.0 (35.0–52.0) F12: 517 (246–1219) F12: 701 (476–1157)
: NR : NR : NR : NR
Ladeiras-Lopes [15] B: 88.7 ± 23.4 B: 84.6 ± 18.9 B: 58.4 ± 3.8 B: 60.1 ± 3.6 B: 52 (29–78) B; 42 (14–52) B: 9.3 ± 1.9 B: 8.6 ± 1.9
MITT 6: 4.50 (14.81) MITT 6: 2.57 (15.43) MITT 6: 7.38 (34.02) MITT 6: 6.43 ± 22.4 MITT 6: − 0.69 ± 1.28 MITT 6: 0.28 ± 1.10
12: − 4.12 (17.06) 12: − 0.20 (16.33) 12: 3.25 (19.49) 12: 3.32 ± 12.38 12: − 0.31 ± 1.60 12: 0.12 ± 1.28
24: − 0.29 (15.30) 24: 3.45 (14.75) 24: 9.71 (31.83) 24:1.35 ± 32.86 24: − 0.57 ± 1.61 24: 0.02 ± 1.54
Larsen [16] B: 98 ± 25 B: 92 ± 25 B: 36 ± 9 B: 39 ± 6 B: 353 [222–896] B: 364 [94–744] B: 12 [11,12,13,14] B: 11 [9,10,11,12,13,14]
F3: 97 ± 22 F3: 94 ± 29 F3: 37 ± 10 F3: 38 ± 11 F3: 442 [194–1190] F3:357 [103–562] F3: 11 [9,10,11,12,13,14] F3: 11 [9,10,11,12,13,14,15]
3: NR 3: NR 3: NR 3: NR 3: NR 3: NR 3: NR 3: NR
Mohan [14] B; 48.7 ± 6.5 B; 46.0 ± 9.3 12 (MITT): − 3.58 ± 7.9 12 (MITT): − 3.53 ± 6.6 B: 957.8 ± 1029 B: 796.5 ± 1247   
12 (MITT): − 2.71 ± 2.31 12 (MITT): − 1.34 ± 2.66 12 (PP): − 4.11 ± 8.4 12 (PP): − 3.90 ± 6.81 12 (MITT):309 ± 1390 12 (MITT):99 ± 475
12 (PP): − 3.12 ± 1.95 12 (PP): − 1.29 ± 2.67 12 (PP): 376 ± 1479 12 (PP): 70 ± 458
Sardu [34] B: 94.11 ± 22.13 B: 93.54 ± 21.88 B: 52 ± 7 B:52 ± 7     
F; 56.13 ± 16.18 F; 79.81 ± 16.83 F12: 57 ± 5 F12: 54 ± 8
12: NA 12: NA
Stakos [35] B: 123 ± 23.6 B: 127 ± 29.2       
12: − 8.1 ± 3.4 12: − 2.9 ± 2.9
24: − 16.8 ± 7.0 24: − 0.2 ± 4.1
Velázquez [18] B: 99.7 ± 20 B: 96 ± 26 B: 71 ± 55 B: 71 ± 40    B: 9.5 ± 2.5 B: 10.6 ± 2.3
F6: 89 ± 18 F6: 98 ± 23 F6: 73 ± 58 F6: 68 ± 29 F6: 9.59 ± 2.1 F6: 10.4 ± 1.5
6: NR 6: NR 6: NR 6: NR 6: NR 6: NR
Wong [17]    B: 34 ± 8 B: 30 ± 8 BNP BNP   
4: 0.35 + 5.50 4: − 1.10 + 4.20 B:131.7 ± 158.5 B: 187.1 ± 251.3
4: − 20.2 ± 78.7 4: 7.5 ± 131.2
  1. Data was presented as mean ± standard deviation or median [interquartile range]
  2. B: Baseline, F3: Final value at 3 months, F4: Final value at 4 months, F6: Final value at 6 months, F12: Final value at 12 months
  3. 3: Change at 3 months, 4: Change at 4 months, 6: Change at 6 months; 12: Change at 12 months, 24: Change at 24 months
  4. C: Control group; E: Experimental group
  5. MITT modified intention to treat, NR not reported, PP per protocol
  6. LVMI was indexed to height1.7